News|Articles|February 13, 2025
Executive Summary: Addressing Regulatory Requirements for CRISPR sgRNA Purity with Orthogonal Chromatography
Author(s)Agilent
The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
2
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
3
What Are the Benefits of Single-Use in CGT Manufacturing?
4
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
5